Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups
Cecilie Askeland et al.
SCIENTIFIC REPORTS (2020)
Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma
Jose J. G. Marin et al.
CANCERS (2020)
Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer
Stephanie Papin et al.
BRAIN SCIENCES (2020)
Novel Functions of the Neurodegenerative-Related Gene Tau in Cancer
Ricardo Gargini et al.
FRONTIERS IN AGING NEUROSCIENCE (2019)
Nuclear Tau, p53 and Pin1 Regulate PARN-Mediated Deadenylation and Gene Expression
Jorge Baquero et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Prognostic Role of High Stathmin 1 Expression in Patients with Solid Tumors: Evidence from a Meta-Analysis
Qingyan Mao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients
Sayaka Obayashi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments
Rong Biaoxue et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma
Lin Yurong et al.
Oncotarget (2016)
Expression, phosphorylation, localization, and microtubule binding of tau in colorectal cell lines
Md Nazmul Huda et al.
APPLIED BIOLOGICAL CHEMISTRY (2016)
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease
Dawn H. W. Lau et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2016)
Anti-STMN1 therapy improves sensitivity to antimicrotubule drugs in esophageal squamous cell carcinoma
Shuai Wang et al.
TUMOR BIOLOGY (2015)
Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy
Jie Zhou et al.
TUMOR BIOLOGY (2015)
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
Dong-Hoe Koo et al.
TUMOR BIOLOGY (2015)
Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer
Wei Nie et al.
LABORATORY INVESTIGATION (2015)
Stathmin 1 in normal and malignant hematopoiesis
Joao Agostinho Machado-Neto et al.
BMB REPORTS (2014)
Genetic characterization of p27kip1 and stathmin in controlling cell proliferation in vivo
Stefania Berton et al.
CELL CYCLE (2014)
Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Y. Lu et al.
CURRENT MOLECULAR MEDICINE (2014)
Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition
Yu Lu et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2014)
Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Anna Mietelska-Porowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells
Yong Wu et al.
CELLULAR ONCOLOGY (2014)
Reduced STMN1 expression induced by RNA interference inhibits the bioactivity of pancreatic cancer cell line Panc-1
J. Li et al.
NEOPLASMA (2014)
Tau protein kinases: Involvement in Alzheimer's disease
Ludovic Martin et al.
AGEING RESEARCH REVIEWS (2013)
Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer
C. Miceli et al.
CANCER GENE THERAPY (2013)
Platinum-Based Agents for Individualized Cancer Treatment
X. Chen et al.
CURRENT MOLECULAR MEDICINE (2013)
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
Maura Sonego et al.
EMBO MOLECULAR MEDICINE (2013)
Stathmin 1 is a potential novel oncogene in melanoma
J. Chen et al.
ONCOGENE (2013)
Relationship Between Gastric Cancer Tau Protein Expression and Paclitaxel Sensitivity
Qiong Wang et al.
PATHOLOGY & ONCOLOGY RESEARCH (2013)
Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer
Bin Ke et al.
TUMOR BIOLOGY (2013)
Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression
Serban San-Marina et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2012)
Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer
Maria T. Baquero et al.
CANCER (2012)
Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells
M. Long et al.
CANCER GENE THERAPY (2012)
Low Expression of Stathmin in Tumor Predicts High Response to Neoadjuvant Chemotherapy with Docetaxel-Containing Regimens in Locally Advanced Breast Cancer
Xu-Li Meng et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2012)
EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Rong Biao-xue et al.
CURRENT CANCER DRUG TARGETS (2011)
Stathmin: a protein with many tasks. New biomarker and potential target in cancer
Barbara Belletti et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Downregulation of Stathmin Is Involved in Malignant Phenotype Reversion and Cell Apoptosis in Esophageal Squamous Cell Carcinoma
Feng Wang et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis
Manimalha Balasubramani et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2011)
Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules
Nan Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
Maria T. Baquero et al.
BREAST CANCER RESEARCH (2011)
Tau in Alzheimer Disease and Related Tauopathies
K. Iqbal et al.
CURRENT ALZHEIMER RESEARCH (2010)
Tumor suppressor interactions with microtubules: keeping cell polarity and cell division on track
Paula Hernandez et al.
DISEASE MODELS & MECHANISMS (2010)
Pathological implications of cell cycle re-entry in Alzheimer disease
David J. Bonda et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2010)
Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
Yu-Yun Shao et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Stathmin1 Overexpression Associated With Polyploidy, Tumor-Cell Invasion, Early Recurrence, and Poor Prognosis in Human Hepatoma
Sen-Yung Hsieh et al.
MOLECULAR CARCINOGENESIS (2010)
Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells
M. A. Matrone et al.
ONCOGENE (2010)
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
Hirokuni Ikeda et al.
BREAST CANCER RESEARCH (2010)
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors
Anita L. Bane et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Lajos Pusztai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy:: an immunohistochemical study
Rastko Golouh et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death
Meihua Sui et al.
CANCER RESEARCH (2007)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
Elizabeth Alli et al.
MOLECULAR PHARMACOLOGY (2007)
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2007)
Neuronal cell cycle re-entry mediates Alzheimer disease-type changes
Andrew McShea et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2007)
Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer
Yoko Oishi et al.
JOURNAL OF HUMAN GENETICS (2007)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tau phosphorylation: physiological and pathological consequences
WH Stoothoff et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2005)
Selective estrogen receptor modulators:: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells
J Frasor et al.
CANCER RESEARCH (2004)
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
L Buée et al.
BRAIN RESEARCH REVIEWS (2000)
Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors
G Brattsand
BRITISH JOURNAL OF CANCER (2000)
Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours
PA Curmi et al.
BRITISH JOURNAL OF CANCER (2000)